gilead glp-1 Got questions about medications and cancer? 💬 Join us for an informative session exploring how GLP-1 medications work, what current guidelines say for cancer patients and survivors, and what emerging research backed formula is designed to support digestion and reduce common discomforts like bloating Lilly, Gilead lead pharma's M&A

Athanasiadis DI, Martin A, Kapsampelis P, Monfared S, Stefanidis D

In the STEP 1 trial, once-weekly 2.4mg semaglutide produced a mean 14.9% body-weight reduction over 68 weeks establishing GLP-1 agonism as a leading anti-obesity mechanism

March 18, 2025 Motion filed by Eli Lilly Eli Lilly is pursuing a motion asking that the court determine that a proper gastroparesis diagnosis should be premised on objective testing that is contemporaneous

No in-person visits Flexible appointment times Medication delivered to your home Ongoing communication with your provider Explore more insights and resources on our GLP-1 Blog